Etoposide in Patients With COVID-19 Infection

Summary

This is a randomized, open-label phase II study designed to evaluate the safety and efficacy of etoposide in patients with the 2019 novel coronavirus (COVID-19) infection. Randomization will be performed with a 3:1 allocation ratio. Treatment will be comprised of etoposide administered intravenously at a dose of 150 mg/m2 on Days 1 and 4 in patients with COVID-19 infection meeting eligibility criteria. Subsequent doses of etoposide will be allowed if the investigator and treating physician believe the patient had clinical benefit from etoposide therapy but subsequently has evidence of recurrent clinical deterioration. Subjects randomized to control will receive standard of care treatment. No placebo will be used.

Timeline

Start

2020-05-08

Primary completion

2022-07-01

Completion

2022-07-01

Outcome

Outcome not reported

Stopped (Enrollment): “Slow accrual, change in COVID prevalence, availability of effective vaccine”

Drugs

Indications